PARIS--(BUSINESS WIRE)--EOS imaging (NYSE Euronext, FR0011191766 – EOSI), the pioneer in orthopaedic 2D/3D imaging, today announced that the EOS imaging system has been installed at The Children’s Hospital of Philadelphia (CHOP), the top ranked children’s hospital in the United States for orthopaedics as well as for overall care. The EOS System will be incorporated into regular clinical practice to obtain full-body, weight-bearing 2D/3D scans and enable improved diagnosis of musculoskeletal conditions.
Marie Meynadier, CEO of EOS imaging, said, “The adoption of EOS by the leading children’s hospital in the United States is a further recognition of our technology for musculoskeletal pathologies, which include spinal deformities and lower limb conditions that require frequent and precise imaging in children. With a radiation dose delivery much lower than the current industry standard and a more informed 3D diagnosis, EOS is changing the game and we look forward to expanding its use to all pediatric centers throughout the world.”
The EOS system provides full-body images of patients in a natural standing or seated position in both 2D and 3D. The system also delivers a radiation dose that has been measured to be nine times lower than that of computed radiography X-ray1 and 20 times lower than basic CT scans2 in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction. Recent research published in JAMA Pediatrics further confirms the need for imaging dose reduction, concluding that lowered radiation dose for pediatric populations could dramatically reduce associated cancer incidence3.
As the first U.S. children’s hospital, CHOP has a history of innovation and excellence. The Division of Orthopedic Surgery at CHOP is one of the most active centers for pediatric orthopaedic care in the world, and the hospital has been ranked No. 1 for orthopaedics by U.S. News & World Report in its “Best Children’s Hospitals” 2012-13 survey. It also tied for the top overall pediatric hospital in the same survey.
For more information on the EOS technology, please visit www.eos-imaging.com.
About EOS imaging:
EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union (EU). Backed by an installed base of over 60 sites and more than 350,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2012 the Group employed 63 people including an R&D team of 23 engineers, and posted 2012 consolidated revenue of €9.42 million. The Group is based in Paris and holds a United States subsidiary in Cambridge (Massachusetts) and offices in Montreal (Canada) and Germany.
For further information, please visit our website at www.eos-imaging.com.
EOS imaging is listed on Compartment C of the NYSE Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI
Next update: half year 2013 revenues: July 17, 2013 after market close
1 S. Parent et al. Diagnostic imaging of spinal deformities: Reducing patients radiation dose with a new slot-scanning x-ray imager. Spine. April 2010
2 D. Folinais et al. Lower Limb Torsional assessment: comparison EOS/CT Scan. JFR 2011.
3 DL Miglioretti. The Use of Computed Tomography in Pediatrics and the Associated Radiation Exposure and Estimated Cancer Risk. JAMA Pediatrics. Online June 10, 2013, via http://archpedi.jamanetwork.com/article.aspx?articleid=1696279.